DOCSLIB.ORG

2015 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2015 Annual Report ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver. Consider some of the long term, we operate under a decentralized changes we are facing in the future global management approach, and we do all health care market: $)"*3."/µ4-&55&3 * 1PQVMBUJPOTPGEFWFMPQFEOBUJPOTBSF base gives us a unique perspective. While we aging rapidly – and we know the elderly are pleased to see that health care is a focus consume about seven times the health in the dialogue among government officials, care resources as younger people. politicians, and other stakeholders, we must ensure that the discussion isn’t just about .JEEMFDMBTTFTBSFFYQBOEJOHJONBOZ developing nations – and we know that cost of care alone. In fact, a disproportionate those developing economies cannot grow focus on pharmaceutical pricing, which fast enough to meet the demand of nearly represents approximately 14%* of total U.S. two billion people who want and deserve health spending, puts us at risk of missing the greater access to quality health care. bigger picture. 1BUJFOUTBSFCFDPNJOHJODSFBTJOHMZ involved in their own health care decisions In this discussion we have to put the patient – and we know we must deliver a holistic in the center and reward innovations that approach to meet their needs and drive better outcomes and long-term value. expectations; integrating wellness solutions, We realize it is the responsibility of all WE HAVE TO innovative new medicines and advanced stakeholders to also consider the economic PUT THE PATIENT technologies. and financial implications of health care, so IN THE CENTER that we have a high quality, innovative, and & REWARD At Johnson & Johnson, we believe the sustainable approach in all that we do. INNOVATIONS most important contribution we can make THAT DRIVE to the dynamic challenges we are facing is The promise of innovation in health care BETTER innovation – innovation in products, services, is great, but it comes with the need for OUTCOMES & solutions and in everything we do. As I think forward-focused investment in R&D, a holistic LONG-TERM back on how far we’ve come, the advances in approach to evolving global health care VALUE. health care are remarkable. The average life markets and bold future-facing strategies. expectancy continues to rise; and diseases, such as HIV, that were once considered a OUR BROAD BASE STRUCTURE IS A death sentence are now treatable. Cures and STRATEGIC CHOICE, NOT JUST OUR treatments reaching the market today are not HERITAGE, AND IT IS ONE THAT IS only improving quality of life for many patients, GROUNDED IN PERFORMANCE. extending life for others, and contributing Our broad base in human health care extends to the productivity of our society, but they our reach, capabilities and strategic advantages are also helping to reduce caregiver burden, for patients, providers and consumers disability, and health care spending in other around the world, and ultimately benefits our parts of the system. shareholders. We review and discuss our structure with our Board of Directors, and we In this environment, ensuring access to believe it has a number of inherent advantages important medicines and medical procedures given the challenges and opportunities in remains a key objective for us, and our broad today’s evolving health care marketplace. ** $)"*3."/µ4-&55&3 Our broad base enables us to: OUR FOCUS IS ON MANAGING $SFBUFBOEBDDFTTHSPXUIPQQPSUVOJUJFT FOR THE LONG TERM—BUILDING across multiple sectors of the health ENDURING EQUITY FOR OUR BRANDS care market. AND BUILDING SHAREHOLDER VALUE OVER TIME. #FBTUSBUFHJDQBSUOFSPGDIPJDFGPS information technology companies and Johnson & Johnson has a set of clear innovative start-ups that can benefit from objectives for creating long-term value. We the deep health care expertise Johnson expect global health care to grow at three & Johnson can uniquely provide. to five percent over the next five years, and we have an objective to grow our 8PSLXJUIMPDBMHPWFSONFOUTBOEQVCMJD health organizations, where we are sales organically at a faster rate than the collaborating more than ever to address market. We also intend to grow our earnings the world’s most pressing health challenges. faster than sales. When we combine these objectives with our plans to continue OUR BROAD 1SPWJEFPVSDVTUPNFSTXJUICSPBEFS creating value through strategic acquisitions BASE IN HUMAN offerings of products, solutions and HEALTH CARE partnership opportunities with us, particularly and partnerships, as well as our strong EXTENDS in large health care systems focused dividend yield, we believe the result to on attracting patients, improving patient be a compelling basis for long-term total OUR REACH, outcomes and reducing the cost of care. shareholder return. CAPABILITIES & STRATEGIC $SFBUFQSPEVDUQMBUGPSNTBOETZTUFNT ADVANTAGES that cross categories and establish new Johnson & Johnson also has a rigorous FOR PATIENTS, sources of innovation through convergent and disciplined portfolio review program PROVIDERS & combination products. We are excited about focused on creating long-term shareholder the promise of convergent technologies in value, and this applies to all our businesses. CONSUMERS categories like lung cancer, vision care, We regularly review this approach with AROUND THE biosurgery, robotics, obesity and diabetes. our Board of Directors, and we have a WORLD. 3FBMJ[FBEWBOUBHFTPGTDBMFUPBDIJFWF track record of taking decisive actions, enterprise efficiencies and capabilities including divestitures and acquisitions, across all sectors. We are targeting as in order to meet changing industry and much as $1 billion in operational savings consumer dynamics. by 2018, to support our growth. Additionally, our disciplined capital allocation Because of its many advantages, our strategy allows us to capitalize on the broad base ultimately helps us deliver right opportunities to create greater long- strong, consistent and sustainable financial term value for our shareholders, while also performance. And most importantly, it allows investing in our businesses for the future. us to create better products, more valuable Our capital allocation strategy starts with services and improve outcomes for patients, paying dividends to our shareholders. consumers and their families. Next, we seek value-creating strategic $)"*3."/µ4-&55&3 *** acquisitions and partnership opportunities. As an enterprise, we continue to focus Finally, we consider other prudent ways to on delivering on our financial and quality return value to shareholders such as share commitments. Consistent with our long-term repurchase programs. strategy, we exceeded our 2015 adjusted operational earnings per share growth During 2015, we increased our dividend for the goal and met our operational sales and 53rd consecutive year, we invested nearly $2.5 free cash flow goals**, while executing billion in licensing, acquisitions and strategic against our enterprise priorities for long- partnerships, and we announced a $10 billion term value creation. share repurchase program in October. The success of our strategies is predicated THE SUCCESS Over the past decade, we have supported on the strength of our leaders and our OF OUR our organic growth programs and prioritized talented, diverse employees across the STRATEGIES IS business needs while also investing globe, with their broad base of experience PREDICATED about 30 percent of our free cash flows** helping to drive results. Our goal is to attract ON THE in merger and acquisition opportunities. and retain the best talent in order to deliver STRENGTH OF Approximately 70 percent has been returned the best outcomes. We’ve made significant OUR LEADERS & to our shareholders in the form of dividends investments, both internally
Load more

Recommended publications
  • Learner Notification International Society for Heart & Lung
    Learner Notification International Society for Heart & Lung Transplantation (ISHLT) 41st Annual Meeting & Scientific Sessions Virtual Experience April 24 – 28, 2021 Live Virtual Acknowledgement of Financial Commercial Support Abbott Medtronic United Therapeutics Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety as partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Physicians (ACCME) The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement - ISHLT designates this live virtual activity for a maximum of 32.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nurses (ANCC) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 ANCC contact hours. Pharmacists (ACPE) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 knowledge-based CPE contact hours.
    [Show full text]
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • Faqs on COVID-19 Vaccine
    COVID-19 Frequently Asked Questions COVID-19 Vaccines About COVID-19 Vaccines Q: Why is a COVID-19 vaccine needed if social distancing and wearing masks prevent the COVID-19 virus from spreading? A: Vaccines boost your immune system, so it will be ready to fight the virus if you are exposed. Vaccination combined with ongoing prevention efforts including wearing face masks that cover the mouth and nose, frequent hand washing and staying at least 6 feet away from others offer the best protection against COVID-19. Q: How many COVID-19 vaccines are available? Which one should I get? A: In the United States, three COVID-19 vaccines have been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and recommended for use by the Centers for Disease Control and Prevention (CDC). These vaccines, manufactured by Pfizer, Moderna, and Johnson & Johnson (Janssen), have all been proven safe and effective at preventing serious illness, hospitalization, and death from COVID-19 disease. The CDC recommends getting the first vaccine available to you for protection from COVID-19. While vaccine supply is limited, individuals likely will not get to choose which vaccine to receive, and will be given what is available from their vaccine provider at the time they receive their immunization. Q: Are all of the COVID-19 vaccines effective? A: Yes. COVID-19 vaccines from Pfizer, Moderna and Johnson & Johnson (Janssen) have been approved for emergency use by the FDA, and recommended for use by the CDC after a rigorous analysis proved their effectiveness. During studies, all the vaccines were shown to prevent serious illness from COVID-19 at high effectiveness rates.
    [Show full text]
  • 2019 Health for Humanity Report
    2019 Health for Humanity Report Progress in Sustainability Report Summary Contents Message from Our Chairman and CEO 3 Sustainability Approach 4 2019 Year in Brief 5 Better Health for All: Tackling the World’s 6 Toughest Health Challenges Better Health for All: Access, Community 7 Health & Innovation Responsible Business Practices 8 Environmental Health 9 UNICEF, the Government of Vietnam and Johnson & Johnson are partnering on a national program to train more than 500 ethnic minority midwives in remote regions to provide effective maternal and child health interventions including early essential newborn care in village clinics and homes. Photo by Paul Bettings Front cover Volunteers, frontline health workers and government officials at the launch of the Umurinzi vaccination program in Rwanda. In October 2019, Johnson & Johnson committed to donating up to 700,000 regimens of Janssen’s investigational Ebola vaccine to support the Ebola outbreak response in Rwanda and the Democratic Republic of the Congo. Photos by Rwanda Ministry of Health 2019 Health2017 for Health Humanity for HumanityReport Summary Report 33 Message from Our Chairman and CEO Dear Johnson & Johnson Stakeholders, We know this mission will always be unfinished, and affirmed unequivocally that there is a fundamental that we will occasionally fall short. But that only serves connection between serving all stakeholders and 2019 was a year of profound change and great contrasts as motivation to move faster than we’ve ever moved generating sustainable, long-term value. around the globe. before in making bigger strides toward some of our most ambitious goals. And as we’ve detailed in this Report, we The demands for global healthcare and responsible We saw unprecedented innovation and encouraging have plenty of positive momentum worth recognizing.
    [Show full text]
  • 2Nd Quarter 2015 Earnings Call Presentation
    2nd Quarter 2015 Earnings Call Presentation July 14, 2015 1 Louise Mehrotra Vice President Investor Relations 2 Note on Forward-Looking Statements These presentations contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Mcneil Consumer : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
    [Show full text]
  • Approved Prenatal Medications Pain Medications • Tylenol
    Approved Prenatal Medications Pain Medications Tylenol (acetaminophen) for minor aches and pains, headaches. (Do not use: Aspirin, Motrin, Advil, Aleve, Ibuprofen.) Coughs/Colds Robitussin (Cough) Robitussin DM (non-productive cough) DO NOT USE TILL OVER 12 WEEKS Secrets and Vicks Throat Lozenges Mucinex Sore Throat Chloraseptic spray Saline Gargle Sucrets and Vicks Throat Lozenges Antihistamines/Allergies Zyrtec Claritin Benadryl Dimetapp Insomnia Benadryl Unison Hemorrhoids Preparation H Tucks Anusol Diarrhea Imodium (1-2 doses- if it persists please notify the office) BRAT diet (bananas, rice, applesauce, toast) Lice RID (only!) DO NOT USE Kwell Itching Benadryl Calamine or Caladryl Lotion Hydrocortisone cream Heartburn, Indigestion, Gas Tums Gas-X Mylanta Pepcid Maalox Zantac *DO NOT USE PEPTO BISMOL- it contains aspirin Decongestants Sudafed Robitussin CF- Only if over 12 weeks Tavist D Ocean Mist Nasal Spray (saline solutions) Nausea Small Frequent Meals Ginger Ale Vitamin B6 Sea Bands Yeast Infections Monistat Mycolog Gyne-lotrimin Toothache Orajel May see dentists, have cavity filled using Novocain or lidocaine, have x-rays with double lead shield, may have antibiotics in the Penicillin family (penicillin, amoxicillin) Sweetners- all should be consumed in moderation with water being consumed more frequently Nutrisweet (aspartame) Equal (aspartame) Splenda (sucralose) Sweet’n Low (saccharin) *note avoid aspartame if you have phenylketonuria (PKU) Constipation Colace Fibercon Citrucel Senokot Metamucil Milk of Magnesia Fiberall Miralax Eczema Hydrocortisone Cream Medications to AVOID Accurate Lithium Paxil Ciprofloxacin Tetracycline Coumadin Other Chemicals to AVOID Cigarettes Alcohol Recreational Drugs: marijuana, cocaine, ecstasy, heroin .
    [Show full text]
  • Research & Development of Vaccines to Prevent SARS-Cov2 Infection
    Monthly update Research & development of vaccines to prevent SARS-coV2 infection Updated May 2021 Disclaimer No vaccine against COVID-19 is approved. This document does not provide guidance on what vaccine or medicines to take. Please avoid self-prescription and always refer to your doctor before making any treatment decision. This document provides a selection of updates on the research and development of vaccines for the current coronavirus infection. Those highlights are for the information of patient organisations/ groups, advocates and people living with a rare disease. EURORDIS takes reasonable steps to verify the accuracy of the information presented. This document does not constitute, and shall not be deemed or construed as, any approval or endorsement by EURORDIS of such product or entity. Updated May 2021 Contents (click to navigate in document) A ‘must-read’ introduction .................................................................................................................................................................................................................................. 4 Resources ........................................................................................................................................................................................................................................................... 5 Vaccines in development ...................................................................................................................................................................................................................................
    [Show full text]
  • Nevada Medicaid Formulary
    Nevada Medicaid-Approved Preferred Drug List Effective August 15, 2021 Legend In each class, drugs are listed alphabetically by either brand name or generic name. Brand name drug: Uppercase in bold type Generic drug: Lowercase in plain type AL: Age Limit Restrictions DO: Dose Optimization Program GR: Gender Restriction OTC: Over the counter medication available with a prescription. (Prescribers please indicate OTC on the prescription) PA: Prior authorization is required. Prior authorization is the process of obtaining approval of benefits before certain prescriptions are filled. QL: Quantity limits; certain prescription medications have specific quantity limits per prescription or per month. SP: Specialty Pharmacy ST: Step therapy is required. You may need to use one medication before benefits for the use of another medication can be authorized. Drug Name Reference Notes *ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS* *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** clonidine hcl er oral tablet extended release Kapvay AL; QL 12 hour *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** atomoxetine hcl oral capsule Strattera DO; AL; QL *AMPHETAMINE MIXTURES*** amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 Adderall XR DO; AL; QL mg amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 Adderall XR AL; QL mg amphetamine-dextroamphetamine oral Adderall DO; AL; QL tablet 10 mg, 12.5 mg, 15 mg, 5 mg, 7.5 mg amphetamine-dextroamphetamine oral Adderall AL tablet 20 mg,
    [Show full text]
  • Frequently Asked Questions
    Frequently Asked Questions Why are these companies included on the "Do Test" list? The following companies manufacture products that are tested on animals at some stage of development. Those marked with a Ƈ are currently observing a moratorium on (i.e., current suspension of) animal testing. Please encourage them to announce a permanent ban. Listed in parentheses are examples of products manufactured by either the company listed or, if applicable, its parent company. For a complete listing of products manufactured by a company on this list, please visit the company's website or contact the company directly for more information. Companies on this list may manufacture individual lines of products that have not been tested on animals. They have not, however, eliminated tests on animals for their entire line of cosmetics and household products. What if a company isn't on either of PETA's lists? Some companies have refused to respond to specific questions about their testing practices. It appears likely that these companies do test on animals at some stage of product development, and their refusal to clarify their testing policies appears to be an attempt to mislead consumers. Other companies may be new. If you find a company not included on our lists, please share the company's contact information with PETA so that we can contact the company directly. Legend Ƈ The company is currently observing a moratorium on animal testing. 3M 3M Corporate 1-888-364-3577 www.solutions.3m.com Headquarters 3M Center St. Paul, Minnesota 55144-1000 Acuvue (Johnson & Johnson) Customer (800) 843-2020 www.acuvue.com/ Relations, D-QA 7500 Centurion Parkway Jacksonville, Florida 32256 Aim (Church & Dwight) P.O.
    [Show full text]